Gridegalutamide
Clinical data | |
---|---|
Other names | BMS-986365; CC-94676 |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C41H45F3N8O5S |
Molar mass | 818.92 g·mol−1 |
3D model (JSmol) | |
| |
|
Gridegalutamide is an investigational oral androgen receptor (AR) degrader being developed for the treatment of metastatic castration-resistant prostate cancer (mCRPC). It belongs to a class of drugs called proteolysis targeting chimeras (PROTACs), which are designed to selectively degrade specific proteins by hijacking the ubiquitin-proteasome system.[1][2] CC-94676 employs a unique dual mechanism of action, combining AR degradation with AR antagonism, potentially offering advantages over traditional AR inhibitors in overcoming resistance mechanisms.[3] Initially developed by Celgene and now under Bristol Myers Squibb, CC-94676 has demonstrated AR protein degradation and suppression of tumor growth in CRPC mouse models.[2] As of 2024, CC-94676 is being evaluated in phase I clinical trials for patients with mCRPC who have progressed on androgen-deprivation therapy and at least one prior secondary hormonal therapy.[1][2]
References
[edit]- ^ a b Salama AK, Trkulja MV, Casanova E, Uras IZ (December 2022). "Targeted Protein Degradation: Clinical Advances in the Field of Oncology". International Journal of Molecular Sciences. 23 (23): 15440. doi:10.3390/ijms232315440. PMC 9741350. PMID 36499765.
- ^ a b c Xie H, Liu J, Alem Glison DM, Fleming JB (2021). "The clinical advances of proteolysis targeting chimeras in oncology". Exploration of Targeted Anti-tumor Therapy. 2 (6): 511–521. doi:10.37349/etat.2021.00061. PMC 9400722. PMID 36046114.
- ^ Rathkopf DE, Patel MR, Choudhury AD, Rasco D, Lakhani N, Hawley JE, et al. (September 2024). "Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer". Annals of Oncology. doi:10.1016/j.annonc.2024.09.005. PMID 39293515.